We continue to see well below consensus prospects for Roche’s selective oestrogen receptor degrader (SERD) giredestrant, facing stiff competition from AZN’s camizestrant and already FDA approved alternative elacestrant [Menarini]. Despite the apparent broader success of the AZN competitor, we only see real first line prospects restricted
